Trinity Biotech PLC (TRIB)
1.802
+0.12
(+7.27%)
USD |
NASDAQ |
May 03, 16:00
1.76
-0.04
(-2.34%)
After-Hours: 20:00
Trinity Biotech SG&A Expense (Quarterly): 6.935M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 6.935M |
September 30, 2023 | 7.681M |
June 30, 2023 | 7.905M |
March 31, 2023 | 8.632M |
December 31, 2022 | 9.672M |
September 30, 2022 | 5.15M |
June 30, 2022 | 5.929M |
March 31, 2022 | 6.234M |
December 31, 2021 | 3.401M |
September 30, 2021 | 6.112M |
June 30, 2021 | 6.591M |
March 31, 2021 | 6.399M |
December 31, 2020 | 9.631M |
September 30, 2020 | 6.429M |
June 30, 2020 | 5.219M |
March 31, 2020 | 6.219M |
December 31, 2019 | 11.64M |
September 30, 2019 | 7.526M |
June 30, 2019 | 6.807M |
March 31, 2019 | 6.729M |
December 31, 2018 | 6.935M |
September 30, 2018 | 7.48M |
June 30, 2018 | 7.687M |
March 31, 2018 | 7.374M |
December 31, 2017 | 5.958M |
Date | Value |
---|---|
September 30, 2017 | 8.026M |
June 30, 2017 | 7.691M |
March 31, 2017 | 7.278M |
December 31, 2016 | 7.584M |
September 30, 2016 | 7.723M |
June 30, 2016 | 8.265M |
March 31, 2016 | 7.228M |
December 31, 2015 | 6.193M |
September 30, 2015 | 7.794M |
June 30, 2015 | 7.186M |
March 31, 2015 | 6.845M |
December 31, 2014 | 6.742M |
September 30, 2014 | 7.321M |
June 30, 2014 | 6.859M |
March 31, 2014 | 6.769M |
December 31, 2013 | 13.29M |
September 30, 2013 | 6.404M |
June 30, 2013 | 5.942M |
March 31, 2013 | 5.531M |
December 31, 2012 | 3.991M |
September 30, 2012 | 5.608M |
June 30, 2012 | 5.803M |
March 31, 2012 | 5.541M |
December 31, 2011 | 4.115M |
September 30, 2011 | 5.489M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
3.401M
Minimum
Dec 2021
11.64M
Maximum
Dec 2019
7.058M
Average
6.591M
Median
Jun 2021
SG&A Expense (Quarterly) Benchmarks
Avadel Pharmaceuticals PLC | 41.30M |
Amarin Corp PLC | 43.94M |
DBV Technologies SA | 6.443M |
Adaptimmune Therapeutics PLC | 16.88M |
Akari Therapeutics PLC | -- |